TRENTON — Attorney General Anne Milgram and Division of Law Director Robert Gilson announced today that the State has entered into a settlement agreement with medical device maker Synthes, Inc. that resolves allegations Synthes failed to disclose financial conflicts-of-interest among doctors who conducted clinical testing on its products.
Under the Assurance of Voluntary Compliance agreement, Synthes must disclose any future payments made by the company to physicians conducting clinical trials on its devices, as well as any investments held by such physicians in the devices they test. A $3 billion global company, Synthes has also agreed to stop paying clinical trial physicians with company stock or stock options.
Based in West Chester, Pa., Synthes is known principally for its work in spinal and trauma products and devices. The state’s investigation focused on allegations that most doctors conducting clinical trials for Synthes’ ProDisc Total Disc Replacement System, ProDisc-L and ProDisc-C had a financial stake in the outcome.